Evidence map›Paper›PMID 34316322›Full record

ArticleStatistics and its interface2021

Extracting scalar measures from functional data with applications to placebo response.

Thaddeus Tarpey, Eva Petkova, Adam Ciarleglio, Robert Todd Ogden

Registry-linked trialAbstract read
In one paragraph

Article in Statistics and its interface, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05480228 (EPPIC-Net EN21-01 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of 80 mg Daily of NRD135S.E1 Versus Placebo in Adult and Elderly Participants With Painful Diabetic Peripheral Neuropathy.), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05480228 phase2completednot on this mapstarted 2022, after this paper: background citation

EPPIC-Net EN21-01 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of 80 mg Daily of NRD135S.E1 Versus Placebo in Adult and Elderly Participants With Painful Diabetic Peripheral Neuropathy.

TypeinterventionalSponsorJames P. Rathmell, MDRan2022 to 2025Enrolled127ConditionsPainful Diabetic NeuropathyArmsNRD135SE.1, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thaddeus TarpeyDepartment of Population Health, New York University, 180 Madison Ave, 5nd Floor, Room 4-53, New York, NY, 10016, USA.
Eva PetkovaDepartment of Population Health, New York University, 180 Madison Ave, 2th Floor, Room 2-55, New York, NY, 10016, USA.
Adam CiarleglioDepartment of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, 950 New Hampshire Avenue, Room 517, Washington, DC, 20052, USA.
Robert Todd OgdenDepartment of Biostatistics, Columbia University, 722 W. 168th Street, 6th Floor, New York, NY 10032, USA.

Funding

Characterizing Placebo ResponseR01MH099003 · NIMH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PETKOVA, EVA, TARPEY, THADDEUS · 2013 to 2021
$4.5M
Statistical and Machine Learning Methods for Integrating Clinical and Multimodal Imaging Data to Select Optimal Antidepressant TreatmentK01MH113850 · NIMH · GEORGE WASHINGTON UNIVERSITY · PI CIARLEGLIO, ADAM · 2018 to 2021
$647k
Identifying Placebo Responders in Drug Treated SubjectsR01MH068401 · NIMH · WRIGHT STATE UNIVERSITY · PI TARPEY, THADDEUS · 2005 to 2007
$565k
NIMH NIH HHS K01 MH113850NIMH NIH HHS R01 MH068401NIMH NIH HHS R01 MH099003
6 · The paper itself

Abstract

In controlled and observational studies, outcome measures are often observed longitudinally. Such data are difficult to compare among units directly because there is no natural ordering of curves. This is relevant not only in clinical trials, where typically the goal is to evaluate the relative efficacy of treatments on average, but also in the growing and increasingly important area of personalized medicine, where treatment decisions are optimized with respect to a relevant patient outcome. In personalized medicine, there are no methods for optimizing treatment decision rules using longitudinal outcomes, e.g., symptom trajectories, because of the lack of a natural ordering of curves. A typical practice is to summarize the longitudinal response by a scalar outcome that can then be compared across patients, treatments, etc. We describe some of the summaries that are in common use, especially in clinical trials. We consider a general summary measure (weighted average tangent slope) with weights that can be chosen to optimize specific inference depending on the application. We illustrate the methodology on a study of depression treatment, in which it is difficult to separate placebo effects from the specific effects of the antidepressant. We argue that this approach provides a better summary for estimating the benefits of an active treatment than traditional non-weighted averages.

Indexed as

Average tangent slopeLongitudinal dataOrdering curvesPlacebo effects

Identifiers

PMID34316322
PMCPMC8313021

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.